{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:32:18Z","timestamp":1767652338429},"reference-count":31,"publisher":"Frontline Medical Communications, Inc.","issue":"4","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1053\/sder.2001.29066","type":"journal-article","created":{"date-parts":[[2007,1,9]],"date-time":"2007-01-09T19:17:37Z","timestamp":1168370257000},"page":"233-241","source":"Crossref","is-referenced-by-count":107,"title":["Pimecrolimus (Elidel, SDZ ASM 981)\u2014Preclinical pharmacologic profile and skin selectivity"],"prefix":"10.12788","volume":"20","author":[{"given":"Anton","family":"Stuetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Grassberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef G.","family":"Meingassner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","reference":[{"key":"10.1053\/sder.2001.29066_bib1","series-title":"Perspectives in Medicinal Chemistry","first-page":"427","article-title":"Immunophilins as drug targets","author":"Stuetz","year":"1993"},{"key":"10.1053\/sder.2001.29066_bib2","series-title":"Psoriasis","first-page":"769","article-title":"Ascomycins","author":"Grassberger","year":"1998"},{"key":"10.1053\/sder.2001.29066_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/13543784.9.1.69","article-title":"Ascomycins: Promising agents for the treatment of inflammatory skin diseases","volume":"9","author":"Paul","year":"2000","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1053\/sder.2001.29066_bib4","first-page":"231","article-title":"Ascomycin, an antifungal antibiotic","volume":"15","author":"Arai","year":"1962","journal-title":"J Antibiotic (Tokyo)"},{"key":"10.1053\/sder.2001.29066_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1523-1747.ep12345542","article-title":"Clearing of psoriasis by a novel immunosuppressive macrolide","volume":"106","author":"Rappersberger","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archderm.134.7.805","article-title":"Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis","volume":"134","author":"Van Leent","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1053\/sder.2001.29066_bib7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1046\/j.1365-2133.2001.04133.x","article-title":"First experience of topical SDZ ASM 981 in children with atopic dermatitis","volume":"144","author":"Harper","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29066_bib8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1365-2133.2001.04134.x","article-title":"SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis","volume":"144","author":"Luger","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29066_bib9","first-page":"853","article-title":"SDZ ASM 981 cream 1% is efficacious and safe in infants aged 3\u201323 months with atopic dermatitis","volume":"117","author":"Ho","year":"2001","journal-title":"Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib10","first-page":"533","article-title":"SDZ ASM 981: A new approach to long-term management of atopic dermatitis in children","volume":"117","author":"Wahn","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2133.2001.04076.x","article-title":"The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: A randomised, double-blind controlled study","volume":"144","author":"Queille-Roussel","year":"2001","journal-title":"Br J Dermatol"},{"issue":"suppl 2","key":"10.1053\/sder.2001.29066_bib12","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0926-9959(98)95038-3","article-title":"Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions","volume":"11","author":"VanLeent","year":"1998","journal-title":"Eur Acad Dermatol Venereol"},{"issue":"suppl 1","key":"10.1053\/sder.2001.29066_bib13","first-page":"91","article-title":"SDZ ASM 981: Pharmacokinetics in adults and children","volume":"14","author":"Allen","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1053\/sder.2001.29066_bib14","article-title":"Consistently low blood levels of pimecrolimus (Elidel, SDZ ASM 981) after occlusive treatment at chronic hand dermatitis","author":"Thaci","year":"2001","journal-title":"Eur Acad Dermatol Venereol"},{"key":"10.1053\/sder.2001.29066_bib15","first-page":"149","article-title":"SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge","volume":"42","author":"Queille-Roussel","year":"2000","journal-title":"Contact Dermatitis"},{"key":"10.1053\/sder.2001.29066_bib16","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1365-2133.1998.02554.x","article-title":"The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion","volume":"139","author":"Mrowietz","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29066_bib17","first-page":"776","article-title":"Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis","volume":"114","author":"Rappersberger","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2133.1999.02974.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology","volume":"141","author":"Grassberger","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29066_bib19","first-page":"440","article-title":"SDZ ASM 981 potently inhibits the induction of coreceptors involved in the accessory cell-dependent activation of inflammation-mediating T cells","volume":"117","author":"Kalthoff","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s004030050343","article-title":"Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner","volume":"290","author":"Hultsch","year":"1998","journal-title":"Arch Derm Res"},{"key":"10.1053\/sder.2001.29066_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1067\/mai.2001.116865","article-title":"The ascomycin macrolactam pimecrolimus (Elidel\u00ae, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils","volume":"108","author":"Zuberbier","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/sder.2001.29066_bib22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2133.1997.tb03788.x","article-title":"A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology","volume":"137","author":"Meingassner","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29066_bib23","first-page":"832","article-title":"SDZ ASM 981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis","volume":"114","author":"Meingassner","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2133.2000.03411.x","article-title":"Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981","volume":"142","author":"Neckermann","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1053\/sder.2001.29066_bib25","first-page":"532","article-title":"SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506","volume":"117","author":"Meingassner","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib26","article-title":"Pimecrolimus (Elidel\u00ae, SDZ ASM 981): Highly effective in models of skin inflammation but low activity in models of immunosuppression","author":"Meingassner","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1053\/sder.2001.29066_bib27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1159\/000236320","article-title":"Antiinflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis","volume":"99","author":"Meingassner","year":"1992","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1053\/sder.2001.29066_bib28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/1523-1747.ep12456939","article-title":"Immunosuppressive macrolides of the type FK 506: A novel class of topical agents for treatment of skin diseases","volume":"98","author":"Meingassner","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1053\/sder.2001.29066_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1354\/vp.37-6-565","article-title":"Morphologic and immunohistochemical features of experimentally induced allergic contact dermatitis in G\u00f6ttingen Minipigs","volume":"37","author":"Vana","year":"2000","journal-title":"Vet Pathol"},{"key":"10.1053\/sder.2001.29066_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0378-5173(00)00665-7","article-title":"Comparison of human skin or epidermis models with human and animal skin in-vitro percutaneous absorption","volume":"215","author":"Schmook","year":"2001","journal-title":"Int J Pharmaceutics"},{"key":"10.1053\/sder.2001.29066_bib31","first-page":"545","article-title":"Gene profiling of blood cells from psoriatic patients after oral treatment with SDZ ASM 981","volume":"117","author":"Kehren","year":"2001","journal-title":"J Invest Dermatol"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562901800134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562901800134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T12:52:05Z","timestamp":1497703925000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/abstract\/pimecrolimus-elidel-sdz-asm-981-preclinical-pharmacologic-profile-and-skin-selectivity\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S1085562901800134"],"URL":"https:\/\/doi.org\/10.1053\/sder.2001.29066","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}